Using platelet-like particles to stop bleeding and improve healing
Official title: Anti-microbial platelet-like-particles to treat internal bleeding and augment subsequent healing
Funded at North Carolina State University Raleigh · NIH-11090495 · Data updated 2026-11-12
This study is looking at a new treatment using tiny particles that act like platelets to help stop bleeding and heal wounds better for people who have been injured, especially those at risk of bleeding too much or getting infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | North Carolina State University Raleigh NIH-funded |
| Lab location | 1 site (Raleigh, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $536,427 |
| NIH project number | 5R01HL162809-03 |
| Project ID | NIH-11090495 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include adults who have experienced traumatic injuries leading to uncontrolled bleeding.
✕Less likely to help
Patients with chronic bleeding disorders or those not experiencing trauma-related bleeding may not benefit from this research.
What this research studies
This research investigates the use of specially designed platelet-like particles to address uncontrolled bleeding after trauma, which is a major cause of death. The approach focuses on enhancing the body's natural clotting process and improving wound healing by targeting specific proteins in the wound environment. By utilizing microgels that mimic platelets, the study aims to create a more effective treatment for patients suffering from traumatic injuries, particularly those with concurrent bleeding and infection risks. The methodology includes developing these particles to bind to fibrin, a key component in blood clotting, to stabilize clots and promote healing.
Why it matters
Potential benefit: If successful, this research could significantly reduce mortality and complications associated with traumatic bleeding and improve recovery outcomes for patients.
How similar studies have gone: Previous research has shown promise in using similar approaches to enhance clotting and healing, indicating potential for success in this novel application.
Where this research is happening
-
North Carolina State University Raleigh
Raleigh, United States Active
Researchers
- Principal investigator: Brown, Ashley Carson — North Carolina State University Raleigh
- Study coordinator: Brown, Ashley Carson
Related research
Other NIH-funded projects on the same topics.
-
Direct measurement of RhD sensitization after early-pregnancy bleeding
This study tests how often Rh immunoglobulin given after bleeding in early pregnancy prevents RhD sensitization in pregnant people.
-
EpiMAX: a new injectable gel that stops GI bleeding quickly and for days
A new injectable hydrogel with epinephrine-loaded microparticles is designed to plug GI bleeds and provide immediate and lasting hemostasis for about 72 hours.
-
Dynamic risk tools to prevent blood clots and bleeding in cancer patients
A new AI-based approach will predict who among people with cancer starting treatment is at higher risk for blood clots or dangerous bleeding, helping doctors tailor preventive care.
-
Bleeding and Platelet Problems in Ehlers-Danlos Syndrome
This NIH grant looks at why people with Ehlers-Danlos syndrome bleed more and how platelet function is involved, with goals that could lead to better care during surgery or emergencies.
-
Long-acting RNA therapy to control fibrinolysis and reduce bleeding
A new RNA treatment delivered in lipids aims to slow down fibrinolysis and lessen bleeding for people with bleeding disorders or severe hemorrhage.
-
Thrombosis and Bleeding Risk in Medical Inpatients
A patient-facing program to better predict who is at risk for blood clots or bleeding during and after hospital stays, and to tailor prevention accordingly.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.